Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

Journal of Virology

Volumn 70, Issue 9, 1996, Pages 5930-5934

  Harrigan, P Richard ^a   Kinghorn, Ian ^a   Bloor, Stuart ^a   Kemp, Sharon D ^a   Nájera, Isabel ^a   Kohli, Arinder ^a   Larder, Brendan A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CODON; DNA SEQUENCE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RESIDUE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; VIRUS GENOME; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0029843986     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.9.5930-5934.1996     Document Type: Article

References (26)

1. Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
2. Boucher, C. A., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
3. Caffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
4. Fischl, M., D. D. Richman, M. Grieco, et al. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex: a double-blind, placebo-controlled trial. N. Engl. J. Med. 317:185-191.
5. Fitzgibbon, J. E., A. E. Farnham, S. J. Sperber, H. Kim, and D. T. Dubin. 1993. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J. Virol. 67:7271-7275.
6. Hammer, S., D. Katzenstein, M. Hughes, H. Grundacker, M. Hirsch, and T. Merigan, for the ACTG 175 Study Team. 1995. Nucleoside monotherapy (MT) vs combination therapy (CT) in HIV infected adults: a randomised double blind placebo controlled trial in persons with CD4 counts between 200 and 500 cells/mm3. Presented at the 5th European Conference on Clinical Aspects and Treatment of HIV Infection, 26 to 29 Sept. 1995, Copenhagen, Denmark.
7. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/ LAV in HTLV-1 carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
8. Hooker, D., G. Tachedjian, A. Soloman, A. Gurusinghe, S. Land, C. Birch, B. Roy, C. Tantillo, E. Arnold, and N, Deacon. High level resistance to AZT in association with a leueine to tryptophan change at amino acid 210 of HIV-1 reverse transcriptase. Presented at the 2nd National Conference on Human Retroviruses and Related Infections, Jan. 29-Feb. 2. Washington, D.C.
9. Ioannidis, J. P., J. C. Cappelleri, J. Lau, P. R Skolnik, B. Melville, T. C. Chalmers, and H. S. Sacks. 1995. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann. Intern. Med. 122:856-66.
10. Katlama, C., D. Ingrand, C. Loveday, A. M. Hill, G. Pearce, H. McDade, and the Lamivudine European HIV Working Group. 1996. Safety and efficacy of lamivudine/zidovudine combination in antiretroviral naive HIV-1 infected patients: a comparison with zidovudine monotherapy. JAMA 276:118-125.
11. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acid. Sci. USA 89:1934-1938.
12. Kellam, P., C. A. B. Boucher, J. M. G. H. Tijnagel, and B. A. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
13. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
14. Larder, B. A. 1995. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:951-957.
15. Larder, B. A., B. Cheesbro, and D. D. Richman. 1990. Susceptibility of zidovudine-sensitive and -resistant human immunodeficiency virus isolates to antiviral agents determined using a quantitative plaque reduction assay. Antimicrob. Agents Chemother. 34:436-441.
16. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
17. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine. Science 246:1155-1158.
18. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
19. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronick, and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature (London) 365:671-673.
20. Mayers, D. L., F. E. McCutchan, E. E. Sanders-Buell, L. I. Merritt, S. Dilworth, A. K. Fowler, C. A. Marks, N. M. Ruiz, D. D. Richman, C. R. Roberts, and D. S. Burke. 1992. Characterization of HIV isolates arising after prolonged zidovudine therapy. J. Acquired Immune Defic. Syndr. 5:749-759.
21. Schooley, R. T., C. Rameriez-Ronda, J. M. A. Lange, D. A. Cooper, J. Lavelle, L. Lefkowitz, M. Moore, B. A. Larder, M. St Clair, P. Reiss, R. McKinnis, K. N. Pennington, P. R. Harrigan, I. Kinghorn, H. Steel, J. F. Rooney, and the Wellcome Resistance Study Collaborative Group. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared to zidovudine monotherapy. J. Infect. Dis., in press.
22. Shafer, R. W., A. K. N. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, T. D. Merigan and the AIDS Clinical Trials Group 143 Virology Group. 1995. Drug resistance and heterogeneous long-term virological responses of Human Immunodeficiency Virus Type-1 infected subjects to zidovudine and didanosine combination therapy. J. Inf. Dis. 172:711-78.
23. Staszewski, S., C. Loveday, P. R. Harrigan, A. M. Hill, L. Verity, H. McDade, and the Lamivudine European HIV Working Group. 1996. The safety and efficacy of lamivudine/zidovudinc combination vs zidovudine monotherapy in patients pretreated with zidovudine. with a CD4 cell count between 100-400: a randomised double blind controlled trial. JAMA 276:111-117.
24. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
25. Volberding, P. A., S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, H. H. Balfour, Jr., R. C. Reichman, J. A. Bartlett, M. S. Hirsch, et al. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl. J. Med. 322:941-949.
26. Yeni, P., on behalf of the DELTA International Co-ordinating Committee. 1995. Preliminary results of the European/Australian DELTA trial: based on data up to 31 May 1995. Presented at the 5th European Conference on Clinical Aspects and Treatment of HIV Infection, 26 to 29 Sept. 1995, Copenhagen, Denmark.